Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations

Mov Disord. 2004 Oct;19(10):1256-8. doi: 10.1002/mds.20194.

Abstract

Amantadine suppressed severe levodopa-induced choreic dyskinesia, which developed at initiation of levodopa therapy, in two siblings manifesting dystonia with motor delay phenotype of GTP cyclohydrolase I deficiency caused by compound heterozygous GCH1 mutations. Our finding suggests a beneficial effect of amantadine on this type of dyskinesia frequently observed in relatively severe dopamine-deficient metabolic disorders.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amantadine / therapeutic use*
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use*
  • Child
  • Chorea / complications
  • Chorea / drug therapy
  • Dopamine Agents / therapeutic use*
  • Dyskinesia, Drug-Induced / drug therapy*
  • Dyskinesia, Drug-Induced / etiology*
  • GTP Cyclohydrolase / genetics*
  • Heterozygote
  • Humans
  • Levodopa / adverse effects*
  • Male
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics*
  • Pedigree
  • Phenotype
  • Point Mutation / genetics*

Substances

  • Antiparkinson Agents
  • Dopamine Agents
  • Levodopa
  • Amantadine
  • GTP Cyclohydrolase